Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014

Journal of Infectious Diseases

Volumn 215, Issue 4, 2017, Pages 510-517

  Shay, David K ^a   Chillarige, Yoganand ^b   Kelman, Jeffrey ^c   Forshee, Richard A ^d   Foppa, Ivo M ^a,e   Wernecke, Michael ^b   Lu, Yun ^d   Ferdinands, Jill M ^a   Iyengar, Arjun ^b   Fry, Alicia M ^a   Worrall, Chris ^c   Izurieta, Hector S ^d,f  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Acumen LLC   (United States)

^c Centers for Medicare and Medicaid Services   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e BATTELLE MEMORIAL INSTITUTE   (United States)

^f UNIVERSIDAD REY JUAN CARLOS   (Spain)

Author keywords

comparative effectiveness; death; influenza vaccines; influenza, human

Indexed keywords

INFLUENZA VACCINE;

AGED; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG MEGADOSE; EMERGENCY WARD; FEMALE; FRAILTY; HOSPITAL PATIENT; HUMAN; ICD-9-CM; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PHARMACY; SEASONAL VARIATION; UNITED STATES; COMPARATIVE STUDY; DOSE RESPONSE; INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; RISK FACTOR; SEASON; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MEDICARE; RISK FACTORS; SEASONS; TREATMENT OUTCOME; UNITED STATES;

EID: 85016929515     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw641     Document Type: Article

References (35)

1. Louria DB, Blumenfeld HL, Ellis JT, Kilbourne ED, Rogers DE. Studies on influenza in the pandemic of 1957-1958. II. Pulmonary complications of influenza. J Clin Invest 1959; 38:213-65.
2. Eickhoff TC, Sherman IL, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA 1961; 176:776-82.
3. DiazGranados CA, Dunning AJ, Kimmel M, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014; 371:635-45.
4. McElhaney JE, Beran J, Devaster JM, et al; Influence65 Study Group. AS03- adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 2013; 13:485-96.
5. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double- blind placebo-controlled trial. JAMA 1994; 272:1661-5.
6. Licensure of a high-dose inactivated influenza vaccine for persons aged or=65 years (Fluzone High-Dose) and guidance for use-United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:485-6.
7. Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25:7656-63.
8. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double- blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009; 200:172-80.
9. Keitel WA, Atmar RL, Cate TR, et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006; 166:1121-7.
10. Izurieta HS, Thadani N, Shay DK, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis. Lancet Infect Dis 2015; 15:293-300.
11. DiazGranados CA, Robertson CA, Talbot HK, Landolfi V, Dunning AJ, Greenberg DP. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines. Vaccine 2015; 33:4988-93.
12. Appiah GD, Blanton L, DMello T, et al; Centers for Disease Control and Prevention (CDC). Influenza activity-United States, 2014-15 season and composition of the 2015-16 influenza vaccine. MMWR Morb Mortal Wkly Rep 2015; 64:583-90.
13. Centers for Disease Control and Prevention. Update: influenza activity-United States, 2011-12 season and composition of the 2012-13 influenza vaccine. MMWR Morbid Mortal Wkly Rep 2012; 61:414-20.
14. Centers for Disease Control and Prevention. Influenza activity-United States, 2012-13 season and composition of the 2013-14 influenza vaccine. MMWR Morbid Mortal Wkly Rep 2013; 62:473-9.
15. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979; 35:69-75.
16. Pope GC, Kautter J, Ellis RP, et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model. Health Care Financ Rev 2004; 25:119-41.
17. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009; 28:3083-107.
18. Bonmarin I, Belchior E, Bergounioux J, et al. Intensive care unit surveillance of influenza infection in France: the 2009/10 pandemic and the three subsequent seasons. Euro Surveill 2015; 20.
19. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004; 292:1333-40.
20. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86.
21. Zhou H, Thompson WW, Viboud CG, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54:1427-36.
22. Estimates of deaths associated with seasonal influenza-United States, 1976-2007. MMWR Morbid Mortal Wkly Rep 2010; 59:1057-62.
23. Epperson S, Blanton L, Kniss K, et al; Influenza Division, National Center for Immunization and Respiratory Diseases, CDC. Influenza activity-United States, 2013-14 season and composition of the 2014-15 influenza vaccines. MMWR Morb Mortal Wkly Rep 2014; 63:483-90.
24. Barr IG, Russell C, Besselaar TG, et al; Writing Committee of the World Health Organization Consultation on Northern Hemisphere Influenza Vaccine Composition for 2013-2014. WHO recommendations for the viruses used in the 2013-2014 northern hemisphere influenza vaccine: Epidemiology, antigenic and genetic characteristics of influenza A(H1N1)pdm09, A(H3N2) and B influenza viruses collected from October 2012 to January 2013. Vaccine 2014; 32:4713-25.
25. Skowronski DM, Janjua NZ, De Serres G, et al. Low 2012-13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 2014; 9:e92153.
26. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Efficacy and immunogenicity of high-dose influenza vaccine in older adults by age, comorbidities, and frailty. Vaccine 2015; 33:4565-71.
27. DiazGranados CA, Dunning AJ, Robertson CA, Talbot HK, Landolfi V, Greenberg DP. Effect of previous-year vaccination on the efficacy, immunogenicity, and safety of high-dose inactivated influenza vaccine in older adults. Clin Infect Dis 2016; 62:1092-9.
28. McLean HQ, Thompson MG, Sundaram ME, et al. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. J Infect Dis 2015; 211:1529-40.
29. Lindegren ML, Griffin MR, Williams JV, et al. Antiviral treatment among older adults hospitalized with influenza, 2006-2012. PLoS One 2015; 10:e0121952.
30. Williams LO, Kupka NJ, Schmaltz SP, Barrett S, Uyeki TM, Jernigan DB. Rapid influenza diagnostic test use and antiviral prescriptions in outpatient settings preand post-2009 H1N1 pandemic. J Clin Virol 2014; 60:27-33.
31. Garvin JH, Redd A, Bolton D, et al. Exploration of ICD-9-CM coding of chronic disease within the Elixhauser Comorbidity Measure in patients with chronic heart failure. Perspect Health Inf Manag 2013; 10:1b.
32. Jackson ML, Nelson JC, Jackson LA. Why do covariates defined by International Classification of Diseases codes fail to remove confounding in pharmacoepidemiologic studies among seniors? Pharmacoepidemiol Drug Saf 2011; 20:858-65.
33. Psaty BM, Siscovick DS. Minimizing bias due to confounding by indication in comparative effectiveness research: the importance of restriction. JAMA 2010; 304:897-8.
34. McGrath LJ, Ellis AR, Brookhart MA. Controlling time-dependent confounding by health status and frailty: restriction versus statistical adjustment. Am J Epidemiol 2015; 182:17-25.
35. Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis 2016; 16:942-51.